From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Clinical data
Trade namesEasyef, Genesoft, Kang He Su, Regen-D[1]
SynonymsRecombinant human epidermal growth factor; rhEGF; DWP-401
Routes of
CAS Number
PubChem CID
CompTox Dashboard (EPA)
ECHA InfoCard100.241.060 Edit this at Wikidata
Chemical and physical data
Molar mass6222.026 g/mol g·mol−1
3D model (JSmol)

Nepidermin (brand name Easyef), also known as recombinant human epidermal growth factor (rhEGF), is a recombinant form of human epidermal growth factor (EGF) and a cicatrizant (a drug that promotes wound healing through formation of scar tissue). It was developed by Daewoong Pharmaceutical.[1][2][3] As a recombinant form of EGF, nepidermin is an agonist of the epidermal growth factor receptor (EGFR), and is the first EGFR agonist to be marketed.[2][3]

It is marketed as an ointment for the treatment of diabetic foot ulcers, wounds, and alopecia (hair loss) in Vietnam, the Philippines, Thailand, and China.[1][2][3]

As of 2017 it was in clinical trials in South Korea for the treatment of stomatitis (inflammation of the mouth or lips) and for reversal of skin side effects caused by erlotinib (an EGFR inhibitor).[2][4]

See also[edit]


  1. ^ a b c "Nepidermin". Retrieved 3 June 2017.
  2. ^ a b c d "Nepidermin". AdisInsight. Retrieved 3 June 2017.
  3. ^ a b c Lau, Hui-Chong; Kim, Aeri (2016). "Pharmaceutical perspectives of impaired wound healing in diabetic foot ulcer". Journal of Pharmaceutical Investigation. 46 (5): 403–423. doi:10.1007/s40005-016-0268-6. ISSN 2093-5552.
  4. ^ Yuan A, Sonis S (2014). "Emerging therapies for the prevention and treatment of oral mucositis". Expert Opin Emerg Drugs. 19 (3): 343–51. doi:10.1517/14728214.2014.946403. PMID 25102771.